Free Trial
→ Is SpaceX really worth 1.78 Trillion? (From InvestPub) (Ad)tc pixel Free GRTX Stock Alerts

Galera Therapeutics (GRTX) Competitors

Galera Therapeutics logo
$0.08 0.00 (0.00%)
As of 06/16/2026 01:45 PM Eastern
Compare

GRTX vs. EDSA, TIL, TCRT, IMMP, and XLO

Should you buy Galera Therapeutics stock or one of its competitors? MarketBeat compares Galera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galera Therapeutics include Edesa Biotech (EDSA), Instil Bio (TIL), Alaunos Therapeutics (TCRT), Prima BioMed (IMMP), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical products" industry.

How does Galera Therapeutics compare to Edesa Biotech?

Galera Therapeutics (NASDAQ:GRTX) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 29.58%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Edesa Biotech is more favorable than Galera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Edesa Biotech
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Galera Therapeutics' return on equity of 0.00% beat Edesa Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -99.34%
Edesa Biotech N/A -286.52%-75.36%

Galera Therapeutics has a beta of 2.59, suggesting that its stock price is 159% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

In the previous week, Edesa Biotech had 2 more articles in the media than Galera Therapeutics. MarketBeat recorded 2 mentions for Edesa Biotech and 0 mentions for Galera Therapeutics. Edesa Biotech's average media sentiment score of 1.20 beat Galera Therapeutics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Galera Therapeutics Neutral
Edesa Biotech Positive

50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Edesa Biotech is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$59.08M$0.640.13
Edesa BiotechN/AN/A-$7.19M-$1.34N/A

Summary

Edesa Biotech beats Galera Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Galera Therapeutics compare to Instil Bio?

Galera Therapeutics (NASDAQ:GRTX) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Galera Therapeutics has a beta of 2.59, suggesting that its share price is 159% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 47.0% of Instil Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Galera Therapeutics' return on equity of 0.00% beat Instil Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -99.34%
Instil Bio N/A -39.76%-22.38%

Instil Bio is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$59.08M$0.640.13
Instil BioN/AN/A-$71.37M-$7.08N/A

In the previous week, Instil Bio had 1 more articles in the media than Galera Therapeutics. MarketBeat recorded 1 mentions for Instil Bio and 0 mentions for Galera Therapeutics. Instil Bio's average media sentiment score of 0.94 beat Galera Therapeutics' score of 0.00 indicating that Instil Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Galera Therapeutics Neutral
Instil Bio Positive

Instil Bio has a consensus target price of $66.00, indicating a potential upside of 755.48%. Given Instil Bio's stronger consensus rating and higher possible upside, analysts clearly believe Instil Bio is more favorable than Galera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Instil Bio
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Instil Bio beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Galera Therapeutics compare to Alaunos Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Galera Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.07, indicating that its share price is 207% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Alaunos Therapeutics' average media sentiment score of 0.43 beat Galera Therapeutics' score of 0.00 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Galera Therapeutics Neutral
Alaunos Therapeutics Neutral

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$59.08M$0.640.13
Alaunos TherapeuticsN/AN/A-$4.18M-$2.13N/A

Galera Therapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -99.34%
Alaunos Therapeutics N/A -165.94%-123.50%

50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Galera Therapeutics beats Alaunos Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Galera Therapeutics compare to Prima BioMed?

Galera Therapeutics (NASDAQ:GRTX) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Galera Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market.

Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,351.19%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Prima BioMed is more favorable than Galera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Prima BioMed
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Prima BioMed had 12 more articles in the media than Galera Therapeutics. MarketBeat recorded 12 mentions for Prima BioMed and 0 mentions for Galera Therapeutics. Prima BioMed's average media sentiment score of 0.10 beat Galera Therapeutics' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the news media.

Company Overall Sentiment
Galera Therapeutics Neutral
Prima BioMed Neutral

Prima BioMed has higher revenue and earnings than Galera Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$59.08M$0.640.13
Prima BioMed$4.08M13.69-$39.78MN/AN/A

Company Net Margins Return on Equity Return on Assets
Galera TherapeuticsN/A N/A -99.34%
Prima BioMed N/A N/A N/A

50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Prima BioMed beats Galera Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Galera Therapeutics compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

In the previous week, Xilio Therapeutics' average media sentiment score of 1.31 beat Galera Therapeutics' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Xilio Therapeutics Positive
Galera Therapeutics Neutral

Xilio Therapeutics has higher revenue and earnings than Galera Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xilio Therapeutics$43.77M1.27-$35.04M-$3.55N/A
Galera TherapeuticsN/AN/A-$59.08M$0.640.13

Xilio Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market. Comparatively, Galera Therapeutics has a beta of 2.59, suggesting that its stock price is 159% more volatile than the broader market.

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by company insiders. Comparatively, 12.9% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Galera Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Galera Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xilio Therapeutics-58.52% -151.42% -27.61%
Galera Therapeutics N/A N/A -99.34%

Xilio Therapeutics currently has a consensus price target of $28.00, indicating a potential upside of 230.19%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Xilio Therapeutics is more favorable than Galera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xilio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Xilio Therapeutics beats Galera Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Galera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRTX vs. The Competition

Export
MetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$13.64M$936.83M$6.49B$12.22B
Dividend YieldN/A4.84%2.67%5.65%
P/E Ratio-0.241.4224.6924.42
Price / SalesN/A141.60495.5191.25
Price / CashN/A20.0644.1356.69
Price / Book-0.047.9710.716.73
Net Income-$59.08M-$4.05M$3.57B$337.78M
7 Day PerformanceN/A3.84%2.56%3.08%
1 Month PerformanceN/A3.59%3.03%4.49%
1 Year PerformanceN/A44.65%28.90%31.54%

Galera Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRTX
Galera Therapeutics
N/A$0.09
flat		N/A+193.1%$13.64MN/AN/A30
EDSA
Edesa Biotech
0.9981 of 5 stars		$6.13
+17.6%		$5.00
-18.4%		+204.4%$54.47MN/AN/A20
TIL
Instil Bio
1.8582 of 5 stars		$7.97
-0.1%		$66.00
+728.0%		-76.9%$54.06MN/AN/A410
TCRT
Alaunos Therapeutics
0.3794 of 5 stars		$2.17
+10.2%		N/A-30.0%$52.99MN/AN/A40
IMMP
Prima BioMed
2.2862 of 5 stars		$0.35
-0.5%		$5.50
+1,453.7%		-79.2%$52.17M$4.08MN/A2,021

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GRTX) was last updated on 6/17/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel